Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice
2018/11/17 by Tim Hendrikx, Yi Duan, Yanhan Wang +14 · 30 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Gut microbiota and health #Liver Disease Diagnosis and Treatment #Diet and metabolism studies
paper · doi:10.1136/gutjnl-2018-317232
Abstract
Objective Antimicrobial C-type lectin regenerating islet-derived 3 gamma (REG3G) is suppressed in the small intestine during chronic ethanol feeding. Our aim was to determine the mechanism that underlies REG3G suppression during experimental alcoholic liver disease. Design Interleukin 22 (IL-22) regulates expression of REG3G. Therefore, we investigated the role of IL-22 in mice subjected to chronic-binge ethanol feeding (NIAAA model). Results In a mouse model of alcoholic liver disease, we found that type 3 innate lymphoid cells produce lower levels of IL-22. Reduced IL-22 production was the result of ethanol-induced dysbiosis and lower intestinal levels of indole-3-acetic acid (IAA), a microbiota-derived ligand of the aryl hydrocarbon receptor (AHR), which regulates expression of IL-22. Importantly, faecal levels of IAA were also found to be lower in patients with alcoholic hepatitis compared with healthy controls. Supplementation to restore intestinal levels of IAA protected mice from ethanol-induced steatohepatitis by inducing intestinal expression of IL-22 and REG3G, which prevented translocation of bacteria to liver. We engineered Lactobacillus reuteri to produce IL-22 ( L. reuteri /IL-22) and fed them to mice along with the ethanol diet; these mice had reduced liver damage, inflammation and bacterial translocation to the liver compared with mice fed an isogenic control strain and upregulated expression of REG3G in intestine. However, L. reuteri /IL-22 did not reduce ethanol-induced liver disease in Reg3g –/– mice. Conclusion Ethanol-associated dysbiosis reduces levels of IAA and activation of the AHR to decrease expression of IL-22 in the intestine, leading to reduced expression of REG3G; this results in bacterial translocation to the liver and steatohepatitis. Bacteria engineered to produce IL-22 induce expression of REG3G to reduce ethanol-induced steatohepatitis.
Cited by
- Gut Bacterial Indole-3-acetic Acid Induced Immune Promotion Mediates Preventive Effects of Fu Brick Tea Polyphenols on Experimental Colitis
- Role of the gut microbiota in type 2 diabetes and related diseases
- Alcohol‐Related Liver Disease and Metabolic Dysfunction‐Associated Steatotic Liver Disease: Molecular Pathogenesis and Therapeutic Interventions
- The Gut‒Liver Axis in Liver Disease: Molecular Mechanisms and Therapeutic Targets
- Microplastics in human body: accumulation, natural clearance, and biomedical detoxification strategies
- Indole-3-Acetic Acid Alleviates Nonalcoholic Fatty Liver Disease in Mice via Attenuation of Hepatic Lipogenesis, and Oxidative and Inflammatory Stress. [europepmc]
- Alcohol or Gut Microbiota: Who Is the Guilty? [europepmc]
- Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. [europepmc]
- Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. [europepmc]
- Gut-Derived Metabolites and Their Role in Immune Dysfunction in Chronic Kidney Disease. [europepmc]
- Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. [europepmc]
- Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. [europepmc]
- Interleukin 22 in Liver Injury, Inflammation and Cancer. [europepmc]
- Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future. [europepmc]
- Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes. [europepmc]
- Gut microbiome, liver immunology, and liver diseases. [europepmc]
- Bacteroides uniformis combined with fiber amplifies metabolic and immune benefits in obese mice. [europepmc]
- Bacteroides ovatus Promotes IL-22 Production and Reduces Trinitrobenzene Sulfonic Acid-Driven Colonic Inflammation. [europepmc]
- Nutritional Components in Western Diet Versus Mediterranean Diet at the Gut Microbiota-Immune System Interplay. Implications for Health and Disease. [europepmc]
- Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis. [europepmc]
- Bacteriophages and their potential for treatment of gastrointestinal diseases. [europepmc]
- Intestinal Barrier in Human Health and Disease. [europepmc]
- New Insights Into Gut-Bacteria-Derived Indole and Its Derivatives in Intestinal and Liver Diseases. [europepmc]
- Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases. [europepmc]
- The interaction among gut microbes, the intestinal barrier and short chain fatty acids. [europepmc]
- Promises of microbiome-based therapies. [europepmc]
- Acetate reprograms gut microbiota during alcohol consumption. [europepmc]
- Applications of synthetic biology in medical and pharmaceutical fields. [europepmc]
- The gut-liver axis and gut microbiota in health and liver disease. [europepmc]
- Alcohol-associated liver disease. [europepmc]
Related